论文部分内容阅读
目的观察以莫西沙星为基础的7d三联疗法对根除Hp感染的临床效果。方法选择122例符合条件的幽门螺杆菌(Hp)阳性的慢性胃炎或消化性溃疡患者,随机分为两组。治疗组:莫西沙星0.4gqd,呋喃唑酮1.1gbid,雷贝拉唑10mgbid;对照组:克拉霉素0.5gbid,呋喃唑酮0.1gbid,雷贝拉唑10mgbid,治疗7d。疗程结束4周后复查Hp,观察临床症状变化及不良反应等。结果治疗组和对照组的Hp根除率、不良反应率分别为93.44%、8.20%和70.49%、27.88%,存在显著性差异(P<0.05),而症状缓解率为95.08%和83.61%,两组无显著性差异(P>0.05)。结论以莫西沙星、呋喃唑酮为基础的7d三联疗法是一种较为理想的Hp根除方案。
Objective To observe the clinical effect of moxifloxacin-based 7d triple therapy on eradication of Hp infection. Methods 122 patients with chronic gastritis or peptic ulcer who were positive for Helicobacter pylori (Hp) were selected and randomly divided into two groups. Treatment group: moxifloxacin 0.4gqd, furazolidone 1.1gbid, rabeprazole 10mgbid; control group: clarithromycin 0.5gbid, furazolidone 0.1gbid, rabeprazole 10mgbid, treatment 7d. 4 weeks after the end of treatment review Hp, observation of clinical symptoms and adverse reactions. Results The Hp eradication rate and adverse reactions of the treatment group and the control group were 93.44%, 8.20% and 70.49%, 27.88%, respectively (P <0.05), and the rates of symptom remission were 95.08% and 83.61% There was no significant difference between the two groups (P> 0.05). Conclusion 7d triple therapy based on moxifloxacin and furazolidone is an ideal Hp eradication program.